Introduction
============

Changes in body composition play an important role in the pathogenesis and progression of chronic heart failure (HF).^[@r1]^ Sarcopenia, which is characterized by a decrease in skeletal muscle mass and strength, affects 19.5% of ambulatory patients with HF,^[@r2]^ and is associated with several alterations such as impaired endothelial function, reduced 6-minute walking distance, and attenuated peak VO~2~.^[@r2],[@r3]^ Although sarcopenia has been frequently described in elderly patients as a consequence of the ageing process, it can also be present in younger patients with HF.^[@r4]^

Resting sympathoexcitation is a hallmark in chronic HF.^[@r5]^ In addition, accumulated evidence shows that this autonomic dysregulation is highly associated with increased morbidity and mortality.^[@r5]^ In normal conditions, sympathetic nervous system exerts anabolic action via β~2~-adrenoceptors on skeletal muscle,^[@r6]^ but in experimental model of HF, the exacerbated sympathetic nervous activity contributes to downregulation of β~2~-adrenoceptors favoring skeletal muscle atrophy and weight loss.^[@r7]^

Reduced parasympathetic activity has also been reported in patients with HF.^[@r8],[@r9]^ Binkley and colleagues ^[@r10]^ showed impaired parasympathetic activity in patients with HF evaluated by heart rate variability. Moreover, heart rate recovery (HRR), an important cardiac deceleration mechanism after maximum effort, can also be used to assess parasympathetic activity immediately after maximal exercise testing.^[@r11]^ Furthermore, HRR is an easy, low-cost, and clinical assessment of vagal reactivation, and provides additional prognostic information.^[@r12]-[@r14]^

Muscle sympathetic nerve activity (MSNA) and HRR, as measures of sympathetic and parasympathetic activity, respectively, have not been studied in sarcopenic patients with HF. Therefore, the aim of this study was to evaluate the impact of autonomic modulation assessed by MSNA (by microneurography technique) and HRR immediately after maximal exercise testing in patients with HF and sarcopenia.

Methods
=======

Study population
----------------

Between May 1, 2016 and December 31, 2017, we prospectively enrolled 116 male outpatients with stable chronic HF. Inclusion criteria were: (1) age between 18 and 65 years old; (2) at least 1 year of HF diagnosis; (3) left ventricular ejection fraction (LVEF) lower than 40% measured by echocardiography; (4) non-ischemic and ischemic etiologies; (5) compensated HF with optimal medication for at least three months prior the study; and (6) New York Heart Association (NYHA) class I to IV.

Patients with autonomic diabetic neuropathy, chronic renal failure with haemodialysis, heart transplantation, pacemaker, muscular dystrophy (i.e. Duchenne muscular dystrophy), any hormonal treatment, history of cancer, ongoing infection, and myocardial infarction with percutaneous coronary intervention or revascularization up to 6 months prior to the study entry, were not included.

Muscle sympathetic nerve activity
---------------------------------

MSNA was directly recorded from the peroneal nerve using the microneurography technique.^[@r15],[@r16]^ Multiunit post-ganglionic muscle sympathetic nerve recordings were made using a tungsten microelectrode placed in the peroneal nerve near the fibular head. Nerve signals were amplified by a factor of 50,000 to 100,000 and band-pass filtered (700 to 2000 Hz). For recording and analysis, nerve activity was rectified and integrated (time constant 0.1 second) to obtain a mean voltage display of sympathetic nerve activity. MSNA was expressed as burst frequency (bursts per minute).

Maximal cardiopulmonary exercise test
-------------------------------------

All patients underwent symptom-limited cardiopulmonary exercise test (Vmax Encore 29 System; VIASYS Healthcare Inc., Palm Springs, California, USA) performed on a cycle ergometer (Ergometer 800S; SensorMedics, Yorba Linda, California, USA), using a ramp protocol with workload increments of 5 or 10 Watts per minute. Oxygen consumption (VO~2~) and carbon dioxide output (VCO~2~) were measured by means of gas exchange on a breath-by-breath basis and expressed as 30-s averages. The patients were initially monitored for 2 minutes at rest when seated on the ergometer; then they were instructed to pedal at a pace of 60-70 rpm and the completion of the test occurred when, in spite of verbal encouragement, the patient reached maximal volitional fatigue. A respiratory exchange ratio (RER) higher than 1.10 was reached for all patients. Heart rate (HR) was monitored continuously at rest, during the test and recovery phase, using a 12-lead digital electrocardiogram (CardioSoft 6.51 ECG/CAM-14, GE Medical Systems Information Technologies, Wisconsin, USA).^[@r17]^

After achieving peak workload, the patients continued to pedal at 10 watts for 2 minutes, followed by 4 minutes seated on the ergometer, this 6-min period was considered the recovery phase. Delta (∆) HRR was calculated by subtracting the HR values at 1^st^ (∆HRR1) and 2^nd^ (∆HRR2) minutes of the recovery phase from the peak HR.^[@r12]^

Body composition and muscle strength
------------------------------------

Body composition measurements - total lean and fat mass - were performed using dual-energy X-ray absorptiometry (DXA) (Lunar iDXA; GE Medical Systems Lunar, Madison, USA). Then, skeletal muscle mass index (SMI) was calculated as the sum of appendicular lean muscle mass of both arms and legs divided by height in meters squared.^[@r18]^

After adjusting handle position, muscle strength was assessed by handgrip dynamometer (Model J00105; Jamar Hydraulic Hand Dynamometer) using the dominant hand in a supinated position with elbow flexed at 90º. There was 1-min rest interval between efforts and the maximum value of three attempts was used.^[@r19]^

Sarcopenia was defined as SMI and muscle strength lower than 7.26 kg/m^2^ and 30 kg, respectively.^[@r20]^

Laboratory Measurements
-----------------------

Blood samples were drawn in the morning after 12h overnight fasting. The laboratory tests included B-type natriuretic peptide (BNP; pg/mL) plasma level, serum sodium (mEq/L), serum potassium (mEq/L), creatinine (mg/dL), haemoglobin level (g/dL), high-sensitivity C-reactive protein (hs-CRP; mg/L), lipid profile (triglyceride, total cholesterol, high-density lipoprotein, and low-density lipoprotein; mg/dL), and fasting glucose (mg/dL).

Statistical analysis
--------------------

Data are presented as mean ± standard deviation and median with lower and upper quartile (95%CI). One-sample Kolmogorov-Smirnov test was used to evaluate the distribution normality of the studied variables. Student\'s t-test and Mann-Whitney U test were used to compare parametric and nonparametric variables, respectively. Chi-square test and Spearman\'s correlation were used as appropriate. The Statistical Package for the Social Sciences version 23 (SPSS Inc., Chicago, Illinois, USA) was used to perform all the statistical analysis. P value lower than 0.05 was considered statistically significant.

Results
=======

Clinical-demographic data
-------------------------

We prospectively enrolled 116 male patients ([Table 1](#t1){ref-type="table"}) with stable chronic HF, 33 of whom were identified to have sarcopenia (28%). Patients with sarcopenia were older, had higher BNP concentration, and lower hemoglobin compared with patients without sarcopenia. No difference was found between sarcopenic and non-sarcopenic patients regarding the dosage of β-blocker medication (20 ± 9.6 vs. 23 ± 10.5 mg b.i.d., p = 0.39; respectively) and medication in general ([Table 1](#t1){ref-type="table"}).

###### 

Demographic and clinical characteristics of the study population

  Variables                             All patients (n = 116)   Patients with sarcopenia (n = 33)   Patients without sarcopenia (n = 83)   P value
  ------------------------------------- ------------------------ ----------------------------------- -------------------------------------- ----------
  Age (y)                               55 ± 9                   59 ± 6                              54 ± 9                                 0.002
  Weight (kg)                           71.1 ± 14.4              59.4 ± 7.4                          75.8 ± 13.8                            \< 0.001
  Height (m)                            1.67 ± 0.07              1.66 ± 0.07                         1.67 ± 0.07                            0.401
  BMI (kg/m^2^)                         25.5 ± 4.5               21.6 ± 2.5                          27.1 ± 4.2                             \< 0.001
  Aetiology (Ischaemic/non-ischaemic)   30/86                    8/25                                22/61                                  1.000
  NYHA class (I/II/III/IV)              40/41/28/7               9/11/11/2                           31/30/17/5                             0.500
  LVEF (%)                              28 ± 8                   26 ± 7                              29 ± 8                                 0.124
  BNP (pg/mL)                           773 ± 877                1159 ± 924                          621 ± 816                              0.006
  Sodium (mEq/L)                        139 ± 3                  138 ± 4                             139 ± 3                                0.383
  Potassium (mEq/L)                     4.6 ± 0.4                4.6 ± 0.3                           4.6 ± 0.4                              0.535
  Creatinine (mg/dL)                    1.24 ± 0.39              1.27 ± 0.47                         1.23 ± 0.35                            0.568
  Haemoglobin (g/dL)                    13.9 ± 1.7               13.3 ± 1.6                          14.1 ± 1.7                             0.022
  hs-CRP (mg/L)                         8.96 ± 16.0              12.4 ± 13.6                         7.6 ± 16.7                             0.147
  Triglyceride (mg/dL)                  118 ± 68                 96 ± 38                             127 ± 75                               0.031
  Cholesterol (mg/dL)                   170 ± 45                 159 ± 37                            174 ± 48                               0.111
  HDL (mg/dL)                           44 ± 15                  47 ± 16                             44 ± 14                                0.306
  LDL (mg/dL)                           103 ± 35                 95 ± 25                             106 ± 38                               0.155
  Fasting glucose (mg/dL)               108 ± 21                 106 ± 24                            109 ± 20                               0.510
  **Medication**                                                                                                                             
  β-blocker                                                      33 (100)                            78 (94)                                0.319
  Statins                                                        18 (55)                             49 (59)                                0.682
  ACEI/ARB                                                       31 (94)                             76 (92)                                1.000
  Diuretics                                                      26 (79)                             62 (75)                                0.811
  Anticoagulants                                                 12 (36)                             32 (39)                                1.000
  Hydralazine                                                    6 (18)                              18 (22)                                0.802
  Isosorbide                                                     6 (18)                              18 (22)                                0.802
  Spironolactone                                                 24 (73)                             58 (70)                                0.824

Data are presented as mean ± SD or %. P value referred to Student\'s t-test and Chi-square test for medication. ACEI, angiotensin converting enzyme inhibitors; ARB: angiotensin receptor blockers; BMI: body mass index; BNP: B-type natriuretic peptide; HDL: high-density lipoprotein; hs-CRP: high-sensitivity C-reactive protein; LDL: low-density lipoprotein; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association.

Muscle sympathetic nerve activity, heart rate recovery and functional capacity
------------------------------------------------------------------------------

Patients with sarcopenia had higher MSNA ([Figure 1](#f1){ref-type="fig"}) and lower ∆HRR1 and ∆HRR2 ([Figure 2](#f2){ref-type="fig"}) when compared with non-sarcopenic patients. There was no statistical difference in resting HR and peak HR between sarcopenic and non-sarcopenic patients.

Figure 1Muscle sympathetic nerve activity (MSNA) in bursts/min. Values are presented as medians with lower and upper quartiles (CI 95%). Note that sarcopenic patients showed an increase of 18% in MSNA.

Figure 2Delta heart rate recovery at 1st (∆HRR1) and 2nd (∆HRR2) minutes immediately after maximal exercise testing. Values are presented as medians with lower and upper quartiles (CI 95%). Note that sarcopenic patients showed a lower HRR at 1st (47% difference) and 2nd minutes (40% difference).

Spearman's correlation showed a positive correlation between appendicular lean muscle mass and ∆HRR1 and ∆HRR2 ([Figures 3A](#f3){ref-type="fig"} and [3B](#f3){ref-type="fig"}, respectively). In addition, we observed a negative correlation between appendicular lean muscle mass and MSNA ([Figure 3C](#f3){ref-type="fig"}).

Figure 3(A) Spearman's correlation between appendicular lean muscle mass and delta heart rate recovery at 1st minute (∆HRR1). (B) Spearman's correlation between appendicular lean muscle mass and delta heart rate recovery at 2nd minute (∆HRR2). (C) Spearman's correlation between appendicular lean muscle mass and muscle sympathetic nerve activity (MSNA).

Absolute VO~2peak~, relative VO~2peak~, and peak workload were significantly lower in patients with sarcopenia than those without. Sarcopenic patients also showed higher ventilatory equivalent for carbon dioxide (VE/VCO~2~) slope and dead space to tidal volume (VD/VT~peak~) than non-sarcopenic patients, whereas VE~peak~ was lower in patients with sarcopenia than those without ([Table 2](#t2){ref-type="table"}).

###### 

Cardiopulmonary, body composition and strength variables of the patients

  Variables                           All patients (n = 116)   Patients with sarcopenia (n = 33)   Patients without sarcopenia (n = 83)   P value
  ----------------------------------- ------------------------ ----------------------------------- -------------------------------------- ----------
  Absolute VO~2peak~(L/min)           1.43 ± 0.48              1.09 ± 0.31                         1.58 ± 0.47                            \< 0.001
  Relative VO~2peak~ (ml/(kg/min))    20.1 ± 6.3               18.3 ± 5.3                          21.0 ± 6.5                             0.036
  Peak workload (Watts)               103 ± 47                 77 ± 27                             115 ± 51                               \< 0.001
  Resting HR (beats/min)              72 ± 13                  75 ± 16                             71 ± 12                                0.254
  HR~peak~(beats/min)                 134 ± 27                 130 ± 27                            135 ± 28                               0.323
  VE/VCO~2~ slope                     35 ± 7                   37 ± 8                              33 ± 7                                 0.015
  VD/VT~peak~                         0.17 ± 0.02              0.19 ± 0.04                         0.16 ± 0.04                            \< 0.001
  VE~peak~(L/min)                     62.5 ± 18.3              53.5 ± 14.1                         66.4 ± 18.4                            \< 0.001
  **Body composition and strength**                                                                                                        
  Total LM (kg)                       49.6 ± 8.4               43.0 ± 5.2                          52.5 ± 8.0                             \< 0.001
  ALM (kg)                            22.2 ± 4.3               18.3 ± 2.3                          23.9 ± 3.8                             \< 0.001
  SMI (kg/m^2^)                       7.97 ± 1.21              6.63 ± 0.58                         8.54 ± 0.92                            \< 0.001
  Fat mass (kg)                       18.2 ± 8.5               12.9 ± 4.9                          20.5 ± 8.8                             \< 0.001
  Fat (%)                             26 ± 8                   22 ± 7                              27 ± 8                                 \< 0.001
  Handgrip strength (kg)              33 ± 8                   26 ± 3                              36 ± 8                                 \< 0.001

Data are presented as mean ± standard deviation or %. P value referred to Student\'s t-test. ALM: appendicular lean muscle mass; HR: heart rate; LM: lean mass; SMI: skeletal muscle mass index; VE: ventilation; VE/VCO~2~: ventilatory equivalent for carbon dioxide; VD/VT: dead space to tidal volume; VO~2~: oxygen consumption.

Body composition and muscle strength characteristics
----------------------------------------------------

Body mass index was lower in sarcopenic patients when compared with non-sarcopenic, with a significant reduction in appendicular lean muscle mass, total lean mass, fat mass, and fat percentage ([Table 2](#t2){ref-type="table"}). SMI and muscle strength assessed by handgrip dynamometer were also lower in patients with sarcopenia compared with those without sarcopenia.

Discussion
==========

The main and new findings of this study are that sarcopenic patients with HF have increased resting MSNA and blunted vagal reactivation after maximal exercise testing when compared with patients without sarcopenia. Moreover, the appendicular lean muscle mass seems to be associated with higher MSNA and blunted HRR. Additionally, as previously demonstrated,^[@r2]^ we also confirmed the reduction in exercise tolerance (decreased peak VO~2~ and peak workload) in patients with HF and muscle wasting.

HF is a complex disease associated with several comorbidities. One of the major co-morbidities observed in patients with advanced chronic HF is sarcopenia, which is associated with poor prognosis.^[@r21]^ Although the aetiology of sarcopenia is multifactorial, several mechanisms have been suggested to explain this decrease in muscle mass in patients with HF, such as increased inflammatory profile,^[@r22]^ increased oxidative stress,^[@r23]^ overactivation of ubiquitin-proteasome system,^[@r24]^ and increased C-terminal agrin fragment (CAF).^[@r25]^ These alterations, acting independently or in combination, may lead to excessive muscle protein degradation and reduced muscle protein synthesis.

Besides the mechanisms mentioned above, exacerbated sympathetic nerve activity seems to be an important pathophysiological feature in HF leading to the loss of skeletal muscle.^[@r6]^ In an experimental model of HF, Bacurau and colleagues ^[@r6]^ showed that sympathetic hyperactivity contributes to the development of skeletal myopathy by changing muscle morphology.^[@r6]^ β~2~-adrenoceptors play a key role in regulating skeletal muscle mass in both anabolic and catabolic state.^[@r26]^ However, chronic sympathetic hyperactivity may be toxic to skeletal muscle,^[@r27]^ which favors weight loss and sarcopenia in patients with HF. Moreover, increased sympathetic outflow is associated with higher chance of arrhythmias,^[@r28]^ and adverse remodeling of the heart.^[@r29]^

Interestingly, pharmacological treatment of HF is focused on blocking sympathetic activity, mainly by using cardio-selective and non-selective β-blockers. ^[@r30]^ Treatment with β-blockers can increase total body fat mass and total body fat content in patients with HF, without apparent improvement in muscle mass.^[@r30],[@r31]^ In this study, we did not observe differences between groups in β-blocker treatment and dosage. In this context, future randomized clinical trials are required to assess the real impact of β-blocker therapy on skeletal muscle mass in patients with HF.

Previous studies showed that HRR has an important prognostic value in the general population ^[@r12]^ and in patients with HF.^[@r32]^ In addition, HRR is a very simple and easy way to indirectly evaluate the reactivation of the parasympathetic nervous system immediately after maximum effort in cardiopulmonary exercise testing.^[@r11]^ Several investigators showed that the kinetic of HRR in a 6-min recovery period was reduced in patients with HF ^[@r33]^ and this reduction seems to be independent of b-adrenergic blocker therapy.^[@r34]^ Ushijima et al.^[@r35]^ showed an association between norepinephrine and HRR in patients with myocardial infarction, arguing that increased sympathetic excitation at maximum exercise may suppress the parasympathetic reactivation leading to HRR attenuation.^[@r35]^

Taken together, the sympathovagal impairment in patients with HF is associated with poor outcome, and this autonomic imbalance may worsen the loss of muscle mass in these patients. In fact, we showed greater MSNA and lower decrease in HRR at 1^st^ and 2^nd^ minutes post-exercise in sarcopenic patients with HF. Furthermore, reduced appendicular lean muscle mass was correlated with lower HRR1 (r = 0.26), HRR2 (r = 0.25) and greater MSNA (r = -0.29).

We recognize limitations in our study. The present study included only male patients, so we are not able to generalize these results to female patients with HF. Further studies are necessary to investigate the influence of sarcopenia on gender-related differences. The date when HF was diagnosed was not available in patients' medical records, and to compensate for this missing information, we included only patients with at least one year of diagnosis. We assessed parasympathetic activity using the HRR as a marker of vagal reactivation. Although our study has a clinical applicability, more studies using HR variability should clarify the role of cardiac autonomic control on sarcopenia in patients with HF.

Conclusion
==========

Sympatho-vagal imbalance seems to be associated with sarcopenia in male patients with HF. These results highlight the importance of a therapeutic approach in patients with muscle wasting and increased peripheral sympathetic outflow.
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